Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Carcinogenesis|November 12, 2019
REToma: a cancer subtype with a shared driver oncogeneTakashi Kohno, Junya Tabata, Takashi Nakaoku
International Cancer Conference Journal|June 1, 2019
Polypoid endometriosis of the ovary and müllerianosis of pelvic lymph nodes mimicking an ovarian carcinoma with lymph node metastasisYasushi Iida, Junya Tabata, Takashi Yorozu, et al.
Frontiers in Oncology|February 29, 2024
Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathwayYasushi Iida, Nozomu Yanaihara, Yuki Yoshino, et al.
Gynecologic Oncology|November 20, 2022
Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathwayNozomu Yanaihara, Yuki Yoshino, Daito Noguchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2019
Application of Artificial Intelligence for Preoperative Diagnostic and Prognostic Prediction in Epithelial Ovarian Cancer Based on Blood BiomarkersEiryo Kawakami, Junya Tabata, Nozomu Yanaihara, et al.
Scientific Reports|April 9, 2021
Interleukin-6 as an enhancer of anti-angiogenic therapy for ovarian clear cell carcinomaToshiyuki Seki, Nozomu Yanaihara, Jason Solomon Shapiro, et al.
Cancer Research|September 27, 2022
Novel Calcium-Binding Ablating Mutations Induce Constitutive RET Activity and Drive TumorigenesisJunya Tabata, Takashi Nakaoku, Mitsugu Araki, et al.
Research Square|November 19, 2025
Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancerJung-Min Lee, Junya Tabata, Tzu-Ting Huang, et al.
Nature Communications|March 17, 2026
Durvalumab and cediranib with and without olaparib in recurrent ovarian cancer: a phase II proof-of-concept studyJunya Tabata, Tzu-Ting Huang, Elena Giudice, et al.
Pageof 1